Bupropion for the Treatment of Methamphetamine Dependence - 1
Information source: National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Amphetamine-Related Disorders
Intervention: Bupropion (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: National Institute on Drug Abuse (NIDA) Official(s) and/or principal investigator(s):
Richard Rawson, Ph.D., Principal Investigator, Affiliation: University of California, Los Angeles
Summary
The purpose of this study is to assess the efficacy and safety of bupropion in reducing
methamphetamine use in subjects with methamphetamine dependence
Clinical Details
Official title: Bupropion for the Treatment of Methamphetamine Dependence
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Primary outcome: Severity addictionMethamphetamine use
Detailed description:
A double-blind, placebo-controlled, parallel-group design study in which 100 subjects will
be randomly assigned to placebo or bupropion for 12 weeks with follow-up assessments 4 weeks
following treatment. Adaptive randomization will be used to balance treatment groups based
on gender.
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Subject must have methamphetamine dependence as determined by the DSM-IV diagnosis
- Subject must be willing to comply with study procedures.
- Ability to verbalize understanding of consent form, provide written consent, and
verbalize willingness to complete study procedures
- Be able to comply with protocol requirements
Exclusion Criteria:
- Please contact site for more information.
Locations and Contacts
Matrix Institute on Addictions, Costa Mesa, California 92627, United States
South Bay Treatment Center, San Diego, California 92105, United States
Pacific Addiction Research Center, Honolulu, Hawaii 96813, United States
Powell Chemical Dependency Center, Des Moines, Iowa 50316, United States
University of Missouri - Kansas City, Kansas City, Missouri 64108, United States
Additional Information
Starting date: July 2003
Last updated: July 21, 2008
|
